Takeda Ventures, Inc.
Cambridge, Massachusetts, United StatesFounded 2001
Takeda Ventures, Inc. (TVI) is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001. It invests in and nurtures innovative life science companies to create strategic growth opportunities aligned with Takeda's R&D focus areas including oncology, rare genetics, neuroscience, and gastrointestinal and inflammation.
Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $67.8M (across 40 rounds with reported amounts).
Portfolio
44
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Team
KH
Karen Hong
Senior Investment Director
MG
Miles Gerson
Global Head and President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
47 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
 Integra Therapeutics | Pre-Seed | — | Sep 2025 |
 Oshi Health | Series C | $60M | Jan 2025 |
 Accipiter | Seed | — | Jan 2025 |
 Seres Therapeutics | Series E | $113M | Jan 2024 |
 OncoResponse | Series D | $13M | May 2023 |
 Ensoma | Series B | $135M | May 2023 |
 hC Bioscience | Series A | $16M | Nov 2022 |
| EEnzyre | Series A | — | Nov 2022 |
 Koneksa Health | Series C | $45M | Feb 2022 |
| IIntegra Therapeutics | Seed | — | Dec 2021 |
 AptiHealth | Series B | $50M | Nov 2021 |
 Tele911 | Seed | — | Nov 2021 |
 Egle Therapeutics | Series A | — | Oct 2021 |
 Turnstone Biologics | Series D | $80M | Jul 2021 |
| RRibon | Series B | $65M | Jul 2021 |
 BridGene Biosciences | Series A | $12M | May 2021 |
 Stride Bio | Series B | $81.5M | Mar 2021 |
| SStrideBio | Series B | $81.5M | Mar 2021 |
 Aspen RxHealth | Series B | $23M | Jan 2021 |
| AArcellx, Inc. | Series C | $115M | Jan 2021 |
| IImmPACT Bio | Series A | — | Aug 2020 |
 Amwell | Series C | $194M | May 2020 |
| AAmerican Well | Series C | $194M | May 2020 |
| RRedPin Therapeutics | Series A | $15.5M | Mar 2020 |
Page 1 of 2
Top Co-Investors
Alexandria Venture Investments8 shared
Sofinnova Partners5 shared
Pappas Capital4 shared
Cormorant Asset Management4 shared
CaaS Capital4 shared
Novo Holdings A/S4 shared
AbbVie4 shared
Surveyor Capital4 shared
Arix Bioscience3 shared
Atlas Venture3 shared
SV Health Investors3 shared
RA Capital Management3 shared
Northpond Ventures3 shared
UCB Ventures3 shared
Vertex Ventures HC3 shared
SR One3 shared
OrbiMed3 shared
New Enterprise Associates3 shared
Novartis Venture Fund3 shared
Bristol Myers Squibb3 shared
Last updated: 8 September 2026